Adam Tomasi

Adam holds a Bachelor of Science in chemistry from the University of California, Berkeley, a and an MBA from the MIT Sloan School of Management. He completed his PhD at the University of California, Irvine, where he was a Fellow of the American Chemical Society and the University of California Regents, and was a post doctoral student with Peter Schultz at The Scripps Research Institute/The Genomics Institute of the Novartis Foundation.

Before joining Alkalos in 2017, he was VP of Corporate Development at ZS Pharma, and later promoted to Chief Scientific Officer. ZS Pharma is a specialty pharmaceutical company focused on the research and development of highly selective ion-trap therapies to treat serious medical conditions. 

​

Adam spent 7 years at Alta partners focused on life science investments. Originally trained as an organic and medicinal chemist, Adam spent the previous 7 years in early-stage drug discovery with Gilead Sciences and Cytokinetics. In his last technical position, he founded and led the Anti-Infectives Medicinal Chemistry Program at Cytokinetics, which was the first group to validate KIP-1 as an anti-fungal target. Adam also played a key role in the creation of Cytokinetics' cardiovascular drug CK-1827452, currently in clinical trials. 

​

Earlier, Adam was a student in the Harvard-MIT Biomedical Enterprise Program; he completed internships at MPM Capital and Lehman Brothers, where he was an Analyst covering the biotech sector, and attended the Harvard Medical School.

Adam completed his fellowship at Alta Partners in San Francisco under mentor Dan Janney as a member of Fellows Class 11.